Karallief Inc. joint-health ingredient is granted US patent

The United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 11,364,255 to Karallief Inc. (Cambridge, MA) for its Karallief Easy Climb, a multi-herbal extract formula for the support of joint discomfort. The patent protects Karallief’s specific composition of herbal ingredients used to develop its nutraceutical ingredient for joint support.

“The issuance of this patent recognizes the innovation of our Easy Climb multi-herbal blend and demonstrates our commitment to developing proprietary ingredients that have proven both safe and effective through rigorous human clinical trials,” Krishna Rajendran, CEO of Karallief, said in a press release.

In a 120-day randomized, double-blind, placebo-controlled clinical trial, published in the International Journal of Basic & Clinical Pharmacology¹, participants experiencing age-related knee concerns took either Easy Climb, an herbal extract with glucosamine or placebo. At the end of the study, the Easy Climb and herbal extract groups experienced an improvement in four areas: an X-ray analysis of joint space width, a knee flexion test, a 30-second chair stand test, and a subjective questionnaire. The Easy Climb group saw a 71-percent decrease in discomfort and a 25-percent increase in joint space width of the tibiofemoral joint, suggesting Easy Climb aided in regenerating connective tissue in the knee joint.

“Securing a patent for a natural product is difficult because it must be truly innovative in order to differentiate the product from other compositions with plant-based ingredients,” said Rajendran. “At Karallief we focus our clinical research on multi-ingredient blends because our research has shown that when two or more herbal extracts are combined, they work interactively together to provide a stronger, synergistic benefit.”

Reference

1. Rajendran K et al. “Assessment of safety and efficacy of Karallief® Easy ClimbTM, an herbal extract blend for supporting joint health: a double-blind, placebo-controlled, randomized clinical trial.” International Journal of Basic & Clinical Pharmacology, vol. 10, no. 1 (2021)